Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Date:1/29/2009

CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EST.

Interested participants and investors may access the conference call at 5 p.m. EST by dialing 877-675-4756 (U.S./Canada) or 719-325-4870 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EST. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8627644.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
2. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
3. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
6. Amicus Therapeutics Opens Research Facility in San Diego
7. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
8. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
9. Amicus Therapeutics Announces First Quarter 2008 Financial Results
10. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , ... August 15, 2017 , ... Kapstone Medical ... 10 years of successes helping medical technology companies and inventors develop and safeguard their ... renowned full-service national engineering firm with a portfolio of clients in the United States ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... of 6” modular downlights designed to stay tightly sealed and perform efficiently for ... damp and wet location listings just aren't enough, such as: hospitals; behavioral health ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... antibodies. Key researchers in the antibody community have recently come together to address ... antibodies in the laboratory. , The team at Thermo Fisher ...
(Date:8/11/2017)... ... August 11, 2017 , ... A staple in the community for more ... incorporate important key elements including a new digital marketing strategy and updated logo. , ... Bill Miller has partnered with the South Texas Blood & Tissue Center for the ...
Breaking Biology Technology:
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
Breaking Biology News(10 mins):